CEO Clarke Atwell from Claris Bio discusses the potential of topically-administered biologic therapies for ocular diseases like Neurotrophic Keratitis. He shares insights on the development progress, funding, and opportunities in the biotech industry. The podcast explores the shift towards patient-friendly eye treatments, the importance of understanding mechanism of action, and the challenges in clinical trials and manufacturing processes.